Breadcrumb Home Business Activities Lundbeckfonden BioCapital Lundbeckfonden BioCapital Portfolio DBV Technologies DBV Technologies Develops patches for desensitization of food allergy using epicutaneous delivery. The lead program is in late stage clinical trials for peanut allergy desensitization. DBV Technologies' website Lundbeckfonden BioCapital Invested 2010 IPO in 2013 – DBV (Euronext Paris) Location Bagneux, Ill-de-France, France